Professor Bob Taylor
Contact information
Research groups
Bob Taylor
Associate Professor
Vivax malaria
Dr Bob Taylor works on drug trials for vivax and falciparum malaria. In contrast with falciparum malaria, vivax malaria can relapse from dormant stage parasites in the patient’s liver. Primaquine is currently the only available drug to prevent relapse infections but can cause severe haemolysis in patients with reduced G6PD activity. Dr Taylor's research aims to determine the most effective and safest way to radically cure vivax malaria.
Podcast interview
Primaquine for vivax and falciparum malaria
Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.
Recent publications
-
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial
Taylor WR. et al, (2023), The Lancet Infectious Diseases, 23, 471 - 483
-
Treatment outcomes and risk factors of death in childhood tuberculous meningitis in Kandahar, Afghanistan: a prospective observational cohort study.
Rahimi BA. et al, (2022), Transactions of the Royal Society of Tropical Medicine and Hygiene, 116, 1181 - 1190
-
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria
(2022), New England Journal of Medicine, 387, 282 - 283
-
A comparative study of the proximity to nomadic travel routes and environmental factors on the occurrence of cutaneous leishmaniasis in Kohgiluyeh and Boyer-Ahmad province, southwestern Iran.
Ghatee MA. et al, (2022), Transboundary and emerging diseases, 69, e547 - e553
-
A family cluster of cutaneous Leishmania major infection unresponsive to intralesional meglumine antimonial: Case reports.
Ziaee M. et al, (2022), Indian journal of medical microbiology, 40, 451 - 454